NASDAQ$VSTM
Verastem Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Verastem Oncology announced the sale of COPIKTRA® rights to Secura Bio and a focus on development of VS-6766 and Defactinib.
Verastem Oncology entered into a definitive agreement to sell its global commercial and development rights to COPIKTRA to Secura Bio for $70 million up-front, with a total deal value up to $311 million plus royalties. Verastem will focus on developing VS-6766 and Defactinib in KRAS mutant solid tumors, with current programs funded until at least 2024.
- Verastem will receive $70 million up-front with a total deal value up to $311 million from Secura Bio.
- Verastem will focus on the development of VS-6766 and Defactinib in KRAS mutant solid tumors.
- Phase 2 registration-directed trials are expected to commence by year end 2020 in low-grade serous ovarian cancer and KRAS mutant non-small cell lung cancer.
- Enrollment in the ongoing investigator-initiated Phase 1/2 FRAME study of VS-6766 and Defactinib is expanding to include pancreatic, KRAS mutant endometrial and KRAS-G12V non-small cell lung cancer cohorts.
Headline financials
Revenue & EPS history
Verastem · Revenue · Quarterly
$4.31M
Forward guidance
Verastem Oncology provides forward-looking statements about its strategy, future plans, and prospects, including the expected sale of COPIKTRA and the potential clinical value of RAF/MEK/FAK combination.
Tailwinds
- The transaction with Secura Bio is expected to close in the third quarter of 2020.
- The FDA was supportive of the Company’s development strategy and adaptive design for LGSOC.
- Verastem expects to commence registration-directed clinical trials for potential accelerated approval in LGSOC and KRASmt NSCLC by the end of 2020.
- The FRAME study is expanding in August 2020 to include new cohorts in pancreatic, KRASmt endometrial and KRAS-G12V NSCLC.
- With the sale of COPIKTRA, Verastem will become a focused development company with reduced annual expenses of approximately $50 million and is in a position of financial strength with a cash runway expected to fund the clinical and regulatory milestones and development of VS-6766 and defactinib in LGSOC and KRASmt NSCLC until at least 2024.
Headwinds
- The satisfaction of closing conditions with respect to the sale of the COPIKTRA assets to Secura Bio.
- The ability of Secura Bio to achieve the clinical and sales milestones necessary to result in additional consideration payable to Verastem.
- The inherent uncertainty in forecasting expected funding needs of the Company in advancing its product candidates.
- The success in the development and potential commercialization of product candidates, including defactinib in combination with VS-6766.
- The occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis or result in unmanageable safety profiles compared to their levels of efficacy.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-1.0%
Avg return
Earnings day
-0.9%
Avg return
5 days after
+7.3%
Avg return
30 days after
44%
24 / 54 earnings
Positive
+26.9%
Q4 2021
Best reaction
-54.5%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.2% | -23.0% | -38.4% | |
| Q4 2025 | +6.2% | +10.0% | -3.1% | |
| Q3 2025 | -2.9% | +3.6% | +27.0% | |
| Q2 2025 | +19.9% | +42.7% | +91.6% | |
| Q1 2025 | +0.0% | -1.4% | -25.7% | |
| Q4 2024 | -2.5% | -6.2% | -15.8% | |
| Q3 2024 | -3.7% | +19.3% | +51.1% | |
| Q2 2024 | +5.9% | +12.2% | +8.1% | |
| Q1 2024 | +3.9% | +15.4% | -70.2% | |
| Q4 2023 | +2.4% | +5.3% | +5.2% | |
| Q3 2023 | -5.5% | -9.6% | +4.2% | |
| Q2 2023 | -2.2% | -4.0% | -3.8% | |
| Q1 2023 | +2.4% | -4.8% | +121.4% | |
| Q4 2022 | -4.4% | +2.2% | -13.3% | |
| Q3 2022 | +0.0% | +2.6% | +12.8% | |
| Q2 2022 | +1.7% | +6.7% | +2.5% | |
| Q1 2022 | -4.0% | -14.3% | +13.5% | |
| Q4 2021 | +26.9% | +20.2% | +26.9% | |
| Q3 2021 | -3.5% | -3.9% | -15.1% | |
| Q2 2021 | -10.8% | -5.6% | -17.0% | |
| Q1 2021 | -5.1% | -0.3% | +49.2% | |
| Q4 2020 | +2.5% | -0.4% | +12.6% | |
| Q3 2020 | +17.2% | +26.2% | +91.8% | |
| Q2 2020 | -2.0% | -0.7% | -20.3% | |
| Q1 2020 | -54.5% | -57.6% | -57.6% | |
| Q4 2019 | -38.3% | -45.3% | +0.7% | |
| Q3 2019 | -18.8% | -18.0% | -0.8% | |
| Q2 2019 | -6.7% | -9.3% | -16.0% | |
| Q1 2019 | -31.7% | -24.6% | -37.2% | |
| Q4 2018 | +12.8% | +4.7% | -8.4% | |
| Q3 2018 | +12.4% | -0.2% | -12.8% | |
| Q2 2018 | +12.7% | +4.8% | +16.9% | |
| Q1 2018 | -2.3% | -3.9% | +21.4% | |
| Q4 2017 | -4.8% | -8.5% | +14.6% | |
| Q3 2017 | -6.5% | -2.3% | +11.8% | |
| Q2 2017 | -7.0% | -21.4% | +29.0% | |
| Q1 2017 | +15.5% | +17.0% | +3.4% | |
| Q4 2016 | +14.5% | +31.0% | +29.7% | |
| Q3 2016 | +0.0% | +10.6% | +4.4% | |
| Q2 2016 | -0.7% | -4.4% | -1.5% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +8.7% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +11.1% | — | — | |
| Q1 2015 | +2.3% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | +0.9% | — | — | |
| Q2 2014 | -3.2% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +0.7% | — | — | |
| Q3 2013 | -5.3% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -0.3% | — | — | |
| Q1 2012 | -2.5% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro